EGFR and lung carcinoma: Because epidermal growth factor receptor (EGFR) mutation accounts 11–22% of lung cancer driver mutations 2, 3, EGFR‐tyrosine kinase inhibitors (TKIs) have significantly improved the treatment outcome of lung cancer patients 4, 5.